PubMed · 2016 · 95 citations · 10 references
Life SciencesImmunologyOncologyCancer ImmunologyImmunotherapyTumor ImmunologyCancer ImmunotherapyCheckpoint Inhibitor TherapyCombination ImmunotherapyImmune Checkpoint InhibitorsImmune Checkpoint RegulationImmune CheckpointsCheckpoint Antagonist TherapyCheckpoint Inhibitor CombinationsCheckpoint Modulation In CancerCombination Checkpoint TherapyImmune Checkpoint Blockade CombinationsImmune Checkpoint Combination TherapyImmune Checkpoint Inhibitor TherapyResistance To Checkpoint Inhibitors
What started as a trickle of new agents that help the body's immune system fight cancer has now become a flood, despite some daunting adverse effects. This report discusses the new drugs, indications, and combinations that continue to emerge.
10
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi, Steven O’Day, David F. McDermott et al. · New England Journal of Medicine · 2010 · 15.2K citations · Full text
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
Caroline Robert, Georgina V. Long, Benjamin Brady et al. · New England Journal of Medicine · 2014 · 5.4K citations · Full text
Medicine, Oncology, Pharmacotherapy +14
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Stephen M. Ansell, Alexander M. Lesokhin, Ivan Borrello et al. · New England Journal of Medicine · 2014 · 3.5K citations · Full text
Medicine, Oncology, Pharmacology +17